TROGARZO 150 mg/mL
ibalizumab · INJECTION, SOLUTION · Theratechnologies Inc.
No Recall History
Plain English
TROGARZO is a injection, solution containing ibalizumab at 150 mg/mL, taken intravenous. Manufactured by Theratechnologies Inc..
Key Facts
- Brand Name
- TROGARZO
- Generic Name
- ibalizumab
- NDC Code (Product)
62064-122- Manufacturer
- Theratechnologies Inc.
- Strength
- 150 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761065
- Drug Class
- CD4-directed Blocking Antibody [EPC]; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]
- Marketing Start
- 04/20/2018
Recall History
No Recall HistoryFrequently Asked Questions
What is TROGARZO used for?
TROGARZO contains ibalizumab. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is TROGARZO a controlled substance?
TROGARZO is not classified as a controlled substance by the DEA.
What is the generic name for TROGARZO?
The generic name for TROGARZO is ibalizumab. There are no other listed brand versions of ibalizumab.
What is the NDC code for TROGARZO 150 mg/mL?
The NDC (National Drug Code) for TROGARZO 150 mg/mL is 62064-122, listed by Theratechnologies Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)